JoNova 7/20/2020
A legacy of the coronavirus pandemic is the dawn of new ways to stop viruses. Here’s another new (old) one — it’s only a small trial, but if it can stop 4 out of 5 people developing the severe form of the disease it will be a gamechanger. If this gets similar numbers on larger trials, then we still need mass production. But national policies will swing on a dime if a safe drug with this much potential appears.
After Coronavirus we might not be so content to accept the annual seasonal virus scourge.
Breakthrough’ treatment slashes virus death risk: studyby Patrick Galey, MedicalXpress
In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the protein interferon beta were at 79 percent lower risk of developing severe disease compared to those who received a placebo.
They were also more than twice as likely to make a full recovery compared with the control group.
The firm behind the treatment, known as SNG001, said the preliminary results suggested “a major breakthrough†in the pandemic.
Interferon beta is a natural cytokine — our bodies produce it during infections, and some think that older people are just not producing enough of it. We may be just replacing something that was meant to be there, or indeed we might be replacing something that
the virus has suppressed.
Interferon beta is a naturally occurring protein, which orchestrates the body’s antiviral responses. There is evidence that deficiency in IFN-beta production by the lung could explain the enhanced susceptibility of these at-risk patient groups to developing severe lower respiratory tract (lung) disease during respiratory viral infections. Furthermore, viruses, including coronaviruses such as SARS-CoV-2 and MERS-CoV, have evolved mechanisms which suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune system.
–
Uni oif Southhampton.More:
http://joannenova.com.au/2020/07/interferon-beta-reduced-risk-of-severe-covid-by-80/